NeuroMetrix Reports Publication of Randomized Controlled Trial of Quell Wearable Pain Relief in Chronic Low Back Pain

- January 23rd, 2019

NeuroMetrix (Nasdaq:NURO) reported publication of results from a randomized controlled trial of Quell in subjects with chronic low back pain in the journal Pain Practice. As quoted in the press release: The paper is titled “Outcome of a High Frequency Transcutaneous Electrical Nerve Stimulator (hfTENS) Device for Low Back Pain: A Randomized Controlled Trial.”  The study … Continued

NeuroMetrix (Nasdaq:NURO) reported publication of results from a randomized controlled trial of Quell in subjects with chronic low back pain in the journal Pain Practice.

As quoted in the press release:

The paper is titled “Outcome of a High Frequency Transcutaneous Electrical Nerve Stimulator (hfTENS) Device for Low Back Pain: A Randomized Controlled Trial.”  The study was conducted by Dr. Robert Jamison and colleagues at the Brigham and Women’s Hospital Pain Management Center in Boston, MA.

The study was a three-month single site, controlled, randomized clinical trial. A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device (experimental group) or “treatment-as usual” (control group).  Study subjects averaged 46.2 ± 12.7 years of age and 60% were female.  All subjects reported chronic low back pain as their primary complaint.  Over half of the subjects (57%) reported multi-site pain.  All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain.  Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale.  All subjects were given Quantitative Sensory Testing at baseline.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Tags

Leave a Reply